PHARMAC announces the funding of pembrolizumab

PHARMAC announces the funding of pembrolizumab

Evolution of evidence underpins PHARMAC’s pembrolizumab funding decision

PHARMAC is pleased to announce the funding of pembrolizumab, following successful commercial negotiations and evolution in evidence, says PHARMAC Director of Operations, Sarah Fitt.

From 1 September, pembrolizumab (Keytruda) will provide an additional treatment option for melanoma patients.

PHARMAC has remained open-minded to funding Keytruda since an application for funding was made by the supplier, Merck Sharp & Dohme (MSD), and has worked constructively with MSD to reach a favourable commercial arrangement.

“Clinical evidence constantly evolves, especially in new areas of medicine, and PHARMAC’s job is to assess new information as it becomes available” says Ms Fitt.

“Since we first received the funding application for pembrolizumab, new information has emerged that has given PHARMAC the confidence we needed to progress the funding decision.

“PHARMAC has been able to adapt to an evolving evidence base and changes in affordability that have come with our negotiations with MSD and an increase in the medicines budget.

“This reflects the flexibility of the PHARMAC model, while allowing us to make the high-quality decisions New Zealanders expect.”

As a part of the deal, PHARMAC will also fund a modified-release tablet form of the antifungal agent posaconazole (Noxafil) from 1 September 2016.

In addition to background information attached, more information on today’s announcement can be found in the notification letter, on the PHARMAC website.

ENDS

© Scoop Media